- Home
- CMMB vs PYPD Comparison
CMMB vs PYPD Comparison
Compare CMMB & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- PYPD
- Stock Information
- Founded
- CMMB 2004
- PYPD 2008
- Country
- CMMB Israel
- PYPD Israel
- Employees
- CMMB N/A
- PYPD N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- CMMB Health Care
- PYPD Health Care
- Exchange
- CMMB Nasdaq
- PYPD Nasdaq
- Market Cap
- CMMB 20.9M
- PYPD 16.3M
- IPO Year
- CMMB N/A
- PYPD 2020
- Fundamental
- Price
- CMMB $1.20
- PYPD $3.41
- Analyst Decision
- CMMB Strong Buy
- PYPD Buy
- Analyst Count
- CMMB 3
- PYPD 2
- Target Price
- CMMB $5.67
- PYPD $12.00
- AVG Volume (30 Days)
- CMMB 145.5K
- PYPD 4.8K
- Earning Date
- CMMB 11-07-2024
- PYPD 11-06-2024
- Dividend Yield
- CMMB N/A
- PYPD N/A
- EPS Growth
- CMMB N/A
- PYPD N/A
- EPS
- CMMB N/A
- PYPD N/A
- Revenue
- CMMB N/A
- PYPD N/A
- Revenue This Year
- CMMB N/A
- PYPD N/A
- Revenue Next Year
- CMMB N/A
- PYPD N/A
- P/E Ratio
- CMMB N/A
- PYPD N/A
- Revenue Growth
- CMMB N/A
- PYPD N/A
- 52 Week Low
- CMMB $0.42
- PYPD $2.95
- 52 Week High
- CMMB $2.55
- PYPD $9.20
- Technical
- Relative Strength Index (RSI)
- CMMB 33.51
- PYPD 43.89
- Support Level
- CMMB $1.29
- PYPD $3.37
- Resistance Level
- CMMB $1.59
- PYPD $3.65
- Average True Range (ATR)
- CMMB 0.16
- PYPD 0.19
- MACD
- CMMB -0.05
- PYPD -0.01
- Stochastic Oscillator
- CMMB 15.94
- PYPD 22.73
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.